El-Tanani, M.; Ahmed, K.A.-A.; Shakya, A.K.; Ammari, W.G.; Al-Shudifat, A.-E.
Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients. Pharmaceuticals 2023, 16, 799.
https://doi.org/10.3390/ph16060799
AMA Style
El-Tanani M, Ahmed KA-A, Shakya AK, Ammari WG, Al-Shudifat A-E.
Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients. Pharmaceuticals. 2023; 16(6):799.
https://doi.org/10.3390/ph16060799
Chicago/Turabian Style
El-Tanani, Mohamed, Khaled Abdul-Aziz Ahmed, Ashok K. Shakya, Wesam G. Ammari, and Abdel-Elah Al-Shudifat.
2023. "Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients" Pharmaceuticals 16, no. 6: 799.
https://doi.org/10.3390/ph16060799
APA Style
El-Tanani, M., Ahmed, K. A. -A., Shakya, A. K., Ammari, W. G., & Al-Shudifat, A. -E.
(2023). Phase II, Double-Blinded, Randomized, Placebo-Controlled Clinical Trial Investigating the Efficacy of Mebendazole in the Management of Symptomatic COVID-19 Patients. Pharmaceuticals, 16(6), 799.
https://doi.org/10.3390/ph16060799